Genomtec S.A.

Warsaw Stock Exchange GMT.WA

Genomtec S.A. Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -964.66 K

Genomtec S.A. Net Cash Used For Investing Activities is USD -964.66 K for the year ending December 31, 2023, a 2.46% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • Genomtec S.A. Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -988.96 K, a -1,776.88% change year over year.
  • Genomtec S.A. Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -52.69 K, a -149.13% change year over year.
  • Genomtec S.A. Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -21.15 K, a 84.21% change year over year.
  • Genomtec S.A. Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD -133.94 K.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
SV Wall Street
Warsaw Stock Exchange: GMT.WA

Genomtec S.A.

CEO Mr. Miron Tokarski Ph.D.
IPO Date March 17, 2021
Location Poland
Headquarters Bierutowska Street 57-59
Employees 17
Sector Healthcare
Industries
Biotechnology Medical Instruments
Description

Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus. Genomtec S.A was founded in 2016 and is based in Wroclaw, Poland.

StockViz Staff

February 6, 2025

Any question? Send us an email